Xeris Biopharma Holdings, Inc. - Common Stock (NQ:XERS)

10.11 +0.04 (+0.40%)

Delayed Quote Updated: 4:00 PM EDT, Oct 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Xeris Biopharma Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Xeris (XERS) Q2 Revenue Jumps 49% ↗

August 07, 2025

Via The Motley Fool

Traders are paying attention to the gapping stocks in Thursday's session. ↗

August 07, 2025

Let's have a look at the gap up and gap down stocks in today's session.

Via Chartmill

XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) Surges 12% After Q2 Earnings Beat and Raised Revenue Guidance ↗

August 07, 2025

Xeris Biopharma (XERS) Q2 2025 results beat estimates with $71.5M revenue (+48.8% YoY) and narrower losses. Stock surged 12.2% pre-market as Recorlev sales soared 136%. Raised full-year guidance to...

Via Chartmill

Topics Earnings

Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance

August 07, 2025

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Earnings Scheduled For May 8, 2025 ↗

May 08, 2025

Via Benzinga

Earnings Outlook For Xeris Biopharma Holdings ↗

May 07, 2025

Via Benzinga

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025

October 23, 2025

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 03, 2025

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris Announces Orange Book Listing of U.S. Patent for Recorlev®

August 25, 2025

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025

July 31, 2025

From Xeris Biopharma Holdings, Inc.

Via Business Wire

XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) – A Strong Growth Candidate Meeting Minervini’s Criteria ↗

July 07, 2025

XERIS Biopharma (XERS) meets Minervini’s Trend Template with strong technicals and high growth momentum, including 47.9% quarterly revenue growth and a 93.95 Relative Strength score.

Via Chartmill

Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day

June 03, 2025

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris Announces Details for Analyst & Investor Day

May 20, 2025

From Xeris Biopharma Holdings, Inc.

Via Business Wire

XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) – A High-Growth Stock Meeting Minervini’s Trend Template ↗

May 13, 2025

XERIS BIOPHARMA (XERS) meets Minervini’s Trend Template with strong technicals and high-growth fundamentals, making it a stock to watch for momentum investors.

Via Chartmill

Xeris Biopharma Reports Record First Quarter 2025 Financial Results

May 08, 2025

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025

May 01, 2025

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

April 17, 2025

From Bright Peak Therapeutics, Inc.

Via GlobeNewswire

Would Mark Minervini consider XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) a top stock pick? ↗

April 07, 2025

Why the high growth investor may take a look at XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS). A fundamental and technical analysis of (NASDAQ:XERS).

Via Chartmill

Xeris Announces Changes to Its Board of Directors

March 28, 2025

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid

March 17, 2025

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris Biopharma - Possibly The Best Pharma Stock ↗

March 11, 2025

The company offers innovative therapies like Gvoke, Keveyis, and Recorlev, and is developing XP-8121 and XeriSol/XeriJect technologies.

Via Talk Markets

Topics Stocks / Equities

Xeris Biopharma Stock Soars To Nearly 4-Year High On Strong 2025 Outlook, Retail Bulls Charge In ↗

March 06, 2025

The company expects full-year revenue of $255 million to $275 million, significantly higher than the $239.77 million analysts had expected.

Via Stocktwits

These stocks are gapping in today's session ↗

March 06, 2025

The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs.

Via Chartmill

Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 Guidance

March 06, 2025

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025

February 27, 2025

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Earnings Scheduled For March 6, 2025 ↗

March 06, 2025

Via Benzinga

Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer

February 24, 2025

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris to Participate in Upcoming Investor Conferences

February 05, 2025

From Xeris Biopharma Holdings, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.